Cytogenetic response according to previous treatment
| Cytogenetic response3-150 . | Total (n = 229) . | Patients previously untreated (n = 148) . | Patients previously treated (n = 81) . |
|---|---|---|---|
| Major3-151 | 37 (16.2) | 23 (15.5) | 14 (17.3) |
| 95% CI (%) | 11.6-21.6 | 10.1-22.4 | 9.8-27.3 |
| Complete | 17 (7.4) | 12 (8.1) | 5 (6.2) |
| Partial | 20 (8.7) | 11 (7.4) | 9 (11.1) |
| Minor | 4 (1.7) | 3 (2.0) | 1 (1.2) |
| Minimal | 30 (13.1) | 22 (14.9) | 8 (9.9) |
| No response | 151 (65.9) | 97 (65.5) | 54 (66.7) |
| Not evaluable | 7 (3.1) | 3 (2.0) | 4 (5.0) |
| Cytogenetic response3-150 . | Total (n = 229) . | Patients previously untreated (n = 148) . | Patients previously treated (n = 81) . |
|---|---|---|---|
| Major3-151 | 37 (16.2) | 23 (15.5) | 14 (17.3) |
| 95% CI (%) | 11.6-21.6 | 10.1-22.4 | 9.8-27.3 |
| Complete | 17 (7.4) | 12 (8.1) | 5 (6.2) |
| Partial | 20 (8.7) | 11 (7.4) | 9 (11.1) |
| Minor | 4 (1.7) | 3 (2.0) | 1 (1.2) |
| Minimal | 30 (13.1) | 22 (14.9) | 8 (9.9) |
| No response | 151 (65.9) | 97 (65.5) | 54 (66.7) |
| Not evaluable | 7 (3.1) | 3 (2.0) | 4 (5.0) |
Values are numbers (%) of patients unless otherwise indicated. CI indicates confidence interval.
A cytogenetic response was defined by the prevalence of Philadelphia-chromosome-positive metaphases, as follows: 0%, complete response; 1%-35%, partial response; 36%-65%, minor response; 66%-95%, minimal response; and more than 95%, no response.
A major cytogenetic response was a complete or partial response.